Uptake of trusts using NHS FDP Inpatients Care Co-ordination Solution (CCS)

Metric name: number of trusts where the NHS FDP Inpatients product has been used operationally and has contributed to the realisation of benefits against one or more of the benefit measures below at the time of measurement.

How this is measured: this is by counting the number of trusts where the NHS FDP Inpatients CCS product is in live operational use and realising benefits (in terms of contributing to any of the benefit metrics below). A trust is counted where the product is actively being used by operational teams to support inpatient care coordination, including reviewing, managing, and taking action on inpatient waiting list data. Active use also includes the use of the product to identify opportunities to optimise theatre utilisation and support patient flow across inpatient pathways.

What this number shows: this shows the overall level of adoption of the NHS FDP Inpatients CCS product across trusts. This number tells us how widely the product has been implemented and where it is being used to support inpatient care coordination and waiting list management.

Total number of additional patients undergoing procedures in theatres

Metric name: number of additional patients treated in theatres following implementation of the NHS FDP inpatient theatre module

How this is measured: the “Additional Number of Patients Treated” field estimates the uplift in treatment volume following product adoption. It is calculated by comparing the actual number of patients treated post-adoption against an expected baseline derived from pre-adoption activity. The calculation has two components: the expected number of cases (baselined from pre-adoption patients treated) and the actual post-adoption number of patients treated. Both are drawn from weekly Model Hospital reports from trusts (excluding trauma cases). The corresponding Model Hospital Metric is “Number of cases in valid elective sessions (weekly).”

Calculation steps:

1. The Model Health System data is merged with FDP Inpatient theatre module adoption date to give a single table to calculate from. This join is done based on Organisation Codes.
2. Pre-adoption baselining:
3. Post-adoption patients treated: The number of patients treated post-adoption is calculated from the reported number of cases. Each week of reported data contributes to the total number of reported weeks, which is used in the calculation in Step D.
4. Bringing it together: For each trust, the additional number of patients treated is calculated by taking the total number of cases post-adoption and subtracting the expected number of cases (the Step B weekly average × the Step C number of reported weeks). This gives the total difference between the baseline (what would be expected) vs the post-adoption (what has happened since adoption).
5. By summing the value in step D across all trusts, the total additional patients treated is calculated.
6. For each trust:
   1. Additional Patients = (post-adoption cases) − (pre-adoption weekly average × number of post-adoption reporting weeks)
   2. Total Additional Patients = sum of the above across all trust

Source of data for the calculation: Model Health System data coupled with product start dates for each trust from the FDP programme team to determine point 0 that enables the pre and post periods to be defined for each trust. NHS England » The Model Health System

What this number shows: This metric shows how this product is helping trusts treat more patients by making better use of theatre capacity. This number reports the benefit of the inpatient theatre product in terms of the extra patients treated in theatres that the NHS FDP product is supporting with, that we have observed over time. Through identifying free theatre slots and matching patients to these available slots, the NHS FDP is contributing to improved theatre productivity and supporting hospitals to treat more patients. This is an observational before/after comparison showing changes to this metric following the introduction of the NHS FDP Inpatient theatre module. We cannot therefore draw conclusions about cause and effect as other variables have not been controlled for.

Total number of patients no longer waiting for treatment, requested for removal from the waitlist

Metric name: number of patients that have been safely removed from the waiting list through data quality operations

How this is measured: This measures the number of patient entries identified for removal from the waiting list using the NHS FDP Inpatients CCS product across all trusts. Each request for removal is counted when it is made through the product. Each time a patient is suggested for waiting list removal through the NHS FDP Inpatient tool, it adds to a count of removals. This metric sums all of the removals suggested by the tool across all trusts using the product. There is no baseline as we have no record of removals before the tool started.

Source of data for the calculation: NHS FDP inpatient product data.

What this number shows: This shows how the NHS FDP Inpatients CCS product is supporting improved accuracy of waiting lists across trusts. This number tells us how many patient records are being identified and removed through data quality processes, including duplicate, inactive or incorrect entries, helping to ensure waiting lists reflect a more accurate and current position.

Uptake of trusts using NHS FDP Outpatient Care Co-ordination Solution

Metric name: number of trusts where the NHS FDP Outpatients product has been used operationally and has contributed to the realisation of benefits against one or more of the benefit measures below at the time of measurement

How this is measured: this is measured by counting the number of trusts where the NHS FDP Outpatients CCS product is in live operational use and realising benefits (in terms of contributing to any of the benefit metrics below). A trust is counted where the product is actively being used by operational teams to support outpatient waiting list management. Active use includes the use of the product to review, manage, and take action on outpatient waiting list data. A trust is counted once where the product is in active operational use.

Source of data for this calculation: NHS FDP programme deployment records and NHS FDP Outpatients CCS product usage data.

What this number shows: this shows the overall level of adoption of the Outpatients CCS product across trusts. This number tells us how widely the product has been implemented and where it is being used to support outpatient waiting list management and drive improvements in data quality and list accuracy.

Total number of patients no longer waiting for treatment, requested for removal from the waitlist

Metric name: Number of patients that have been safely removed from the outpatient waiting list through data quality operations

How this is measured: This measures the number of patient entries identified for removal from the outpatient waiting list using the product across all trusts. This metric shows the total number of patient entries requested for removal from the waiting list using the NHS FDP Outpatients CCS product across all trusts that have been using the product. Each time a patient is suggested for waiting list removal through the FDP Outpatients tool, it adds to a count of removals. This metric sums all of the removals suggested by the tool across all trusts using the product. There is no baseline as we have no record of removals before the tool started.

Source of data for this calculation: NHS FDP outpatient product data.

What this number shows: How the product improves waiting list accuracy and supports better list management. This number tells us how many patient entries are flagged on the waiting list for potential removal due to data quality issues for example, patient duplication or patient deceased or patient has moved. This helps to ensure waiting lists are up to date and accurate.

Uptake of trusts using NHS FDP Referral to Treatment Validation Product

Metric name: Number of trusts where the NHS FDP RTT product has been used operationally and has contributed to the realisation of benefits against one or more of the benefit measures below at the time of measurement

How this is measured: This is measured by counting the number of trusts where the NHS FDP RTT validation product is in live operational use and realising benefits (in terms of contributing to any of the benefit metrics below). A trust is counted where the product is actively being used by operational teams to review, validate, and update patient pathways. A trust is counted once where the product is in active operational use.

Source of data for this calculation: NHS FDP programme deployment records and NHS FDP RTT product usage data.

What this shows: This shows the overall level of adoption of the NHS FDP RTT validation product across trusts. This number tells us how widely the product has been implemented and where it is being used to support the active management, validation, and accurate tracking of patient pathways against referral to treatment standards.

Total number of RTT period validations

Metric name: Total number of RTT validations completed through the NHS FDP RTT tool.

How this is measured: This metric shows the total number of unique RTT validations that have been performed though the NHS FDP validation product, across all trusts that have been using the product. Each time a pathway validation is done in the tool, it adds to this count. This metric does not currently include a baseline comparison.

Source of data for this calculation: NHS FDP RTT validation product data.

What this number shows: This shows how the product is being used to actively review and manage patient pathways. This number tells us how many pathway validations are being completed through the product, supporting timely progression of patients through their care pathway and improving accuracy of RTT reporting.

Total number of RTT period validation closures

Metric name: Total number of RTT periods closed following validation using the NHS FDP RTT validation product across all participating trusts

How this is measured: This metric shows the total number of RTT periods that have been closed following validation using the NHS FDP RTT validation product across all trusts that have been using the product. Each time a validation is completed in the tool with an outcome of ‘Pathway Closure’, it contributes to the total count. This metric sums all RTT pathway closures recorded through the tool across all trusts using the product since its implementation. There is no baseline as we have no record of removals before the tool started.

Source of data for this calculation: NHS FDP RTT validation product data.

What this number shows:  This shows the extent to which patient pathways are being progressed to completion through validation activity. This number tells us how many RTT pathways have been brought to a confirmed outcome, supporting accurate RTT reporting and helping to ensure that pathway status reflects the true position of patient care. This also indicates how the product is supporting timely updates to pathway status and improving confidence in RTT performance reporting across organisations.

Uptake of trusts using NHS FDP OPTICA Discharge Planning product

Metric name: Number of trusts where the NHS FDP OPTICA product has been used operationally and has contributed to the realisation of benefits against one or more of the benefit measures below at the time of measurement

How this is measured: This is measured by counting the number of trusts where the NHS FDP OPTICA product is in live operational use and realising benefits (in terms of contributing to any of the benefit metrics below). A trust is counted where the product is actively being used by operational teams to support discharge planning, coordinate patient flow, and manage discharge-related tasks. A trust is counted once where the product is in active operational use.

Source of data for this calculation: NHS FDP programme deployment records and NHS FDP OPTICA product usage data.

What this shows: This shows the overall level of adoption of the NHS FDP OPTICA product across trusts. This number tells us how widely the product has been implemented and where it is being used to support discharge planning, improve patient flow, and reduce delays for patients who are ready to leave hospital.

Percentage change in average number of delay days for 7+ stay cohort patients after rolling out FDP OPTICA

Metric name: Percentage change in average delay days for patients with a length of stay of 7 days or more following implementation of NHS FDP OPTICA

How this is measured: This metric compares the average number of delay days for patients staying 7 days or more in hospital, before and after the introduction of NHS FDP OPTICA across all trusts that have been using the product. This comparison is based on performance in the 12 months prior to adoption and the rolling 12 months following implementation. Adoption is defined as 3 months post go-live. A delay day is any day that a patient remains in hospital after they have been declared medically fit to go home.

Calculation steps:

1. The SITREP table is merged with the OPTICA adoption dates to give a single table to calculate from. This join is done using the Org Code.
2. Rows others than metric values relevant to delay days in 7 day+ grouping are excluded.
3. The m associated with LoS 7+ (number of patients who have a length of stay of 7 days and over and who have been assessed and are medically fit to discharge) are grouped.
4. The pre- and post- average for delayed days at each Trust calculated. This is achieved using the adoption dates as the reference point and including any sitrep submission that is: Latest rolling 12 months data from the current date after the adoption date; 12 months data before the adoption date as baseline. Any sitrep before the adoption date is labelled as pre-, and any submission after the adoption date is labelled as post-
5. In case that post adoption reports are less than 12 months, all the data post adoption is labelled as post-.
6. An average is then taken of each of the weekly submissions for pre and post giving the following output: Organisation code – Trust name – Pre OPTICA delay days average – Post OPTICA delay days average
7. The percentage is calculated using this formula for this benefit metric. (Post OPTICA delay days average / Pre OPTICA delay days average) – 1

Source of data for this calculation: NHS England sitrep data. Statistics » Discharge delays (Acute)

What this shows: This shows the extent to which delays in discharge for patients with a length of stay of 7 days or more are being reduced following the use of NHS FDP OPTICA. This number tells us how patient flow is improving by reducing the time patients remain in hospital once they are ready to leave. This is an observational before/after comparison showing changes to this metric following the introduction of the NHS FDP OPTICA solution. We cannot therefore draw conclusions about cause and effect as other variables have not been controlled for.

Percentage change in average number of delay days for 14+ stay cohort patients after rolling out OPTICA

Metric name: percentage change in average delay days for patients with a length of stay of 14 days or more following implementation of the NHS FDP OPTICA tool.

How this is measured: This metric compares the average number of delay days for patients staying 14 days or more in hospital, before and after the introduction of NHS FDP OPTICA across all trusts that have been using the product. This comparison is based on performance in the 12 months prior to adoption and the rolling 12 months following implementation. Adoption is defined as 3 months post go-live. A delay day is any day that a patient remains in hospital after they have been declared medically fit to go home.

Calculation steps:

1. The SITREP table is merged with the OPTICA adoption dates to give a single table to calculate from. This join is done using the Org Code.
2. Rows others than metric values relevant to delay days in 14 day+ grouping are excluded.
3. The Metrics code DIS009 (NHS England » Acute discharge situation report: technical specification) as Delay Days associated with LoS 14+ (number of patients who have a length of stay of 14 days and over and who have been assessed and are medically fit to discharge) are grouped.
4. The pre- and post- average for delayed days at each Trust calculated. This is achieved using the adoption dates as the reference point and including any sitrep submission that is: Latest rolling 12 months data from the current date after the adoption date; 12 months data before the adoption date as baseline. Any sitrep before the adoption date is labelled as pre-, and any submission after the adoption date is labelled as post
5. If post adoption reports are less than 12 months, all the data post adoption is labelled as post.
6. An average is then taken of each of the weekly submissions for pre and post giving the following output: Organisation code – Trust name – Pre OPTICA delay days average – Post OPTICA delay days average
7. The percentage is calculated using this formula for this benefit metric. (Post OPTICA delay days average / Pre OPTICA delay days average) – 1

Source of data for this calculation: NHS England sitrep data. Statistics » Discharge delays (Acute)

What this shows: This shows the extent to which delays in discharge for patients with a length of stay of 14 days or more are being reduced following the use of NHS FDP OPTICA. This number tells us how patient flow is improving for longer-stay patients by reducing the time they remain in hospital once they are ready to leave. This is an observational before/after comparison showing changes to this metric following the introduction of the NHS FDP OPTICA solution. We cannot therefore draw conclusions about cause and effect as other variables have not been controlled for.

Percentage change in average number of delay days for long stay (21+ stay cohort) patients after rolling out OPTICA

Metric name: percentage change in average delay days for patients with a length of stay of 21 days or more following implementation of the NHS FDP OPTICA product.

How this is measured: This metric compares the average number of delay days for patients staying 21 days or more in hospital, before and after the introduction of NHS FDP OPTICA across all trusts that have been using the product. This comparison is based on performance in the 12 months prior to adoption and the rolling 12 months following implementation. Adoption is defined as 3 months post go-live. A delay day is any day that a patient remains in hospital after they have been declared medically fit to go home.

Calculation steps:

1. The SITREP table is merged with the OPTICA adoption dates to give a single table to calculate from. This join is done using the Org Code.
2. Rows others than metric values relevant to delay days in 21 day+ grouping are excluded.
3. The Metrics code DIS008a (NHS England » Acute discharge situation report: technical specification) as Delay Days associated with length of stay 21+ (number of patients who have a length of stay of 21 days and over and who have been assessed and are medically fit to discharge) are grouped.
4. The pre- and post- average for delayed days at each Trust calculated. This is achieved using the adoption dates as the reference point and including any sitrep submission that is: Latest rolling 12 months data from the current date after the adoption date; 12 months data before the adoption date as baseline. Any SITREP before the adoption date is labelled as pre-, and any submission after the adoption date is labelled as post-.
5. If post adoption reports are less than 12 months, all the data post adoption is labelled as post-.
6. An average is then taken of each of the weekly submissions for pre and post giving the following output: Organisation code – Trust name – Pre OPTICA delay days average – Post OPTICA delay days average
7. The percentage is calculated using this formula for this benefit metric. (Post OPTICA delay days average / Pre OPTICA delay days average) – 1

Source of data for this calculation: NHS England sitrep data. Statistics » Discharge delays (Acute)

What this shows: This shows the extent to which delays in discharge for long-stay patients are being reduced following the use of NHS FDP OPTICA. This number tells us how effectively the product supports improved flow and discharge planning for patients with complex or longer hospital stays. This is an observational before/after comparison showing changes to this metric following the introduction of the NHS FDP OPTICA solution and as such causality cannot be inferred. We cannot therefore draw conclusions about cause and effect as other variables have not been controlled for.

Total count of OPTICA patients discharged

Metric name: total number of patients discharged where the NHS FDP OPTICA product has been used to support discharge across all participating trusts.

How this is measured: This metric shows the total number of patients discharged where the NHS FDP OPTICA product has been used to support discharge planning across all trusts that have been using the product. An NHS FDP OPTICA patient is defined as a patient with one or more tasks recorded in the NHS FDP OPTICA tool at the point of discharge.

Source of data for this calculation: NHS FDP OPTICA product data.

What this shows: This shows the scale of discharge activity supported by NHS FDP OPTICA. This number tells us how widely the product is being used to support safe and timely patient discharge from hospital.

Uptake of Trusts using the NHS FDP Cancer360 product

Metric name: Number of trusts where the NHS FDP Cancer360 product has been used operationally and has contributed to the realisation of benefits against one or more of the benefit measures below at the time of measurement

How this is measured: This is measured by counting the number of trusts where the NHS FDP Cancer360 product is in live operational use and realising benefits (in terms of contributing to any of the benefit metrics below). A trust is counted where the product is actively being used by clinical and operational teams to manage cancer pathways, track patient progress, and support decision-making across the pathway.

Source of the data for this calculation: NHS FDP programme deployment records and NHS FDP Cancer 360 product usage data.

What this shows: This shows the overall level of adoption of the NHS FDP Cancer360 product across trusts. This number tells us how widely the product has been implemented and where it is being used to support cancer pathway management, improve visibility of patient progress, and enable more timely diagnosis and treatment.

Average improvement against 28-day Faster Diagnosis Standard (patients receiving a cancer diagnosis or cancer ruled out within 28 days of a cancer referral)

Metric name: change in performance against the 28-day Faster Diagnosis Standard following implementation of NHS FDP Cancer360

How this is measured: This metric compares the 28-day Faster Diagnosis Standard, for the 12 months before and the latest (up to) 12 month rolling average after the introduction of NHS FDP Cancer360 in trusts with the product. Performance is measured from 90 days after go-live to allow time for the product to be embedded in practice. That means trusts that have been live for fewer than 3 months are excluded from this analysis until they pass the adoption date. The calculation is performed on data from all trusts that have been using the product once they have passed the adoption date. However, there is a lag in the Cancer Waiting Times data publication, so this data cannot be reported straight away.

Calculation steps:

1. The data is filtered to trusts where the product has been deployed.
2. Data filtered in step A is merged with go live dates to give a single table to calculate from. This join is done based on Organisation Codes.
3. The Waiting time performance dataset contains 3 performance metrics (28 days, 31 days, and 62 days). We filter to only 28-Day Faster Diagnosis Standard for this metric.
4. The baseline (pre period) is calculated across the12 month period before each trust’s go-live date for the product.
5. To derive performance for each metric period, sum the number of all pathways completed within the 28 days period (numerator) and sum the number of all pathways completed (denominator) and then divide them to get the performance over the period.
6. The overall difference is the difference between Post and Pre go live.

Source of the data for this calculation: NHS England Cancer Waiting Times submissions data. Link Statistics » Cancer Waiting Times

What this shows Whether patients are being diagnosed within target times set by NHS England. It shows the extent to which performance against the 28-day diagnosis standard is improving following the use of NHS FDP Cancer360. This number tells us how many more patients are receiving a diagnosis or having cancer ruled out within the expected timeframe. This is an observational before/after comparison following the introduction of the NHS FDP Cancer360 product. We cannot therefore draw conclusions about cause and effect as other variables have not been controlled for.

Average improvement against 31-day Referral to Treatment target (patients starting treatment within 31 days of a treatment decision)

Metric name: change in performance against the 31-day decision to treatment standard following implementation of NHS FDP Cancer360

How this is measured: This metric compares performance against the 31-day decision to treatment standard, for the 12 months before and the latest (up to) 12 month rolling average after the introduction of NHS FDP Cancer360 in trusts with the product. Performance is measured from 90 days after go-live to allow time for the product to be embedded in practice. This comparison is based on data from all trusts that have been using the product.

Calculation steps:

1. The data is filtered to trusts where the product has been deployed.
2. Data filtered in step A is merged with go live dates to give a single table to calculate from. This join is done based on Organisation Codes.
3. The Waiting time performance dataset contains 3 performance metrics (28 days, 31 days, and 62 days). We filter to only 31-Day DTT to Treatment Standard for this metric.
4. The baseline (pre period) is calculated across the12 month period before each trust’s go-live date for the product.
5. To derive performance for each metric period, sum the number of all pathways completed within the 31 days period (numerator) and sum the number of all pathways completed (denominator) and then divide them to get the performance over the period.
6. The overall difference is the difference between Post and Pre go live.

Source of the data for this calculation: NHS England Cancer Waiting Times submissions data.

What this shows: Whether treatment is starting more quickly after a decision is made. This shows the extent to which treatment is being started within the expected timeframe following a treatment decision. This number tells us how quickly patients are moving from diagnosis to treatment. This is an observational before/after comparison showing changes to this metric following the introduction of the NHS FDP Cancer360 product. We cannot therefore draw conclusions about cause and effect as other variables have not been controlled for.

Average improvement against 62-day Referral to Treatment start target (patients starting first treatment or receiving a benign diagnosis within 62 days of referral)

Metric name: change in performance against the 62-day referral to treatment standard following implementation of NHS FDP Cancer360.

How this is measured: This metric compares performance against the 62-day referral to treatment standard, for the 12 months before and the latest (up to) 12 month rolling average after the introduction of NHS FDP Cancer360 in trusts with the product. Performance is measured from 90 days after go-live to allow time for the product to be embedded in practice. This comparison is based on data from all trusts that have been using the product.

Calculation steps:

1. The data is filtered to trusts where the product has been deployed.
2. Data filtered in step A is merged with go live dates to give a single table to calculate from. This join is done based on Organisation Codes.
3. The Waiting time performance dataset contains 3 performance metrics (28 days, 31 days, and 62 days). We filter to only 62-Day Referral to Treatment Standard for this metric
4. The baseline (pre period) is calculated across the12 month period before each trust’s go-live date for the product.
5. To derive performance for each metric period, sum the number of all pathways completed within the 62 days period (numerator) and sum the number of all pathways completed (denominator) and then divide them to get the performance over the period.
6. The overall difference is the difference between Post and Pre go live.

Source of the data for this calculation: NHS England Cancer Waiting Times submissions data.

What this shows: Whether the overall cancer pathway is becoming faster and more efficient. This shows the extent to which the overall cancer pathway is improving from referral through to treatment. This number tells us how effectively the system is managing end-to-end cancer pathways within national standards. This is an observational before/after comparison showing changes to this metric following the introduction of the NHS FDP Cancer360 product. We cannot therefore draw conclusions about cause and effect as other variables have not been controlled for.

Total number of patients supported on their cancer journey with NHS FDP Cancer360

Metric name: total number of patient pathways supported through use of the NHS FDP Cancer360 product across all participating trusts

How this is measured: This measures the number of patient pathways where the product has been used to take action and support care. Each patient pathway is counted once. This metric shows the total number of patient pathways where a user has created an action using the NHS FDP Cancer360 product across all trusts that have been using the product. Each time a user takes an action in the system that directly impacts a patient pathway, it contributes to this count. This metric sums all pathways supported through the product across all trusts using NHS FDP Cancer360 since its implementation.

Source of the data for this calculation: NHS FDP Cancer360 product data.

What this shows: The scale of support provided to patients throughout their cancer journey. This shows the scale of activity supported by NHS FDP Cancer360 in managing patient pathways. This number tells us how widely the product is being used to support patient care and decision-making across the cancer pathway.